pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Bispecific Antibody · news · pharmadog
← back to Bispecific Antibody
News · Bispecific Antibody
209
stories
20h
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
4d
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
4d
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
5d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
6d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
6d
Spark co-founder Steven Altschuler is back with an immune-resetting biotech
endpoints
6d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
7d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
7d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
7d
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
biospace
8d
6 immunology targets to sustain a mammoth I&I market
biospace
10d
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
biospace
11d
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
12d
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
12d
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
13d
Compass vows to press on with FDA application despite new trial request
biospace
15d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
15d
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
biospace
17d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
18d
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
endpoints
18d
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
19d
Roche turns to Dualitas to find new bispecific approaches for immunology
endpoints
19d
Roche, Dualitas team up to find bispecific drugs for immune diseases
biopharma dive
19d
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
fiercebiotech
19d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
20d
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
21d
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
21d
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
← prev
page 1 of 7
next →
